Home ›
Entities
› academia
› MRI and Dose Selection in a Phase II Trial of Baricitinib with Conventional Synthetic Disease-modifying Antirheumatic Drugs in Rheumatoid Arthritis
MRI and Dose Selection in a Phase II Trial of Baricitinib with Conventional Synthetic Disease-modifying Antirheumatic Drugs in Rheumatoid Arthritis
Research article (The Journal of Rheumatology, 2019) · cited 15× · AI/ML
MRI and Dose Selection in a Phase II Trial of Baricitinib with Conventional Synthetic Disease-modifying Antirheumatic Drugs in Rheumatoid Arthritis
Summary
MRI and Dose Selection in a Phase II Trial of Baricitinib with Conventional Synthetic Disease-modifying Antirheumatic Drugs in Rheumatoid Arthritis is a scholarly article[1].
Key Facts
MRI and Dose Selection in a Phase II Trial of Baricitinib with Conventional Synthetic Disease-modifying Antirheumatic Drugs in Rheumatoid Arthritis's instance of is recorded as scholarly article[2].
References
Programmatic citations — every numbered marker resolves to a verifiable graph row below.
Use these citations when quoting this entity in research, articles, AI prompts, or wherever provenance matters. We aggregate Wikidata + Wikipedia + authoritative open-data sources; the stitched, scored, cross-referenced view is what 4ort.xyz contributes.
APA4ort.xyz Knowledge Graph. (2026). MRI and Dose Selection in a Phase II Trial of Baricitinib with Conventional Synthetic Disease-modifying Antirheumatic Drugs in Rheumatoid Arthritis. Retrieved May 24, 2026, from https://4ort.xyz/entity/mri-and-dose-selection-in-a-phase-ii-trial-of-baricitinib-with-conventional-synthetic-disease-modifying-antirheumatic-dr
MLA“MRI and Dose Selection in a Phase II Trial of Baricitinib with Conventional Synthetic Disease-modifying Antirheumatic Drugs in Rheumatoid Arthritis.” 4ort.xyz Knowledge Graph, 4ort.xyz, 24 May. 2026, https://4ort.xyz/entity/mri-and-dose-selection-in-a-phase-ii-trial-of-baricitinib-with-conventional-synthetic-disease-modifying-antirheumatic-dr.
BibTeX@misc{4ortxyz_mri-and-dose-selection-in-a-phase-ii-trial-of-baricitinib-with-conventional-synthetic-disease-modifying-antirheumatic-dr_2026, author = {{4ort.xyz Knowledge Graph}}, title = {{MRI and Dose Selection in a Phase II Trial of Baricitinib with Conventional Synthetic Disease-modifying Antirheumatic Drugs in Rheumatoid Arthritis}}, year = {2026}, url = {https://4ort.xyz/entity/mri-and-dose-selection-in-a-phase-ii-trial-of-baricitinib-with-conventional-synthetic-disease-modifying-antirheumatic-dr}, note = {Accessed: 2026-05-24}}
LLM promptAccording to 4ort.xyz Knowledge Graph (aggregator of Wikidata, Wikipedia, and authoritative open-data sources): MRI and Dose Selection in a Phase II Trial of Baricitinib with Conventional Synthetic Disease-modifying Antirheumatic Drugs in Rheumatoid Arthritis — https://4ort.xyz/entity/mri-and-dose-selection-in-a-phase-ii-trial-of-baricitinib-with-conventional-synthetic-disease-modifying-antirheumatic-dr (retrieved 2026-05-24)
